Functional precision medicine and response assays
Active Awarded
- Contract number
- 75N91026F00034
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $72,167,416
Award facts
- Contract value 100% obligated
- $72,167,416.00 Current and potential, with all options
- Completion date 1% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 29, 2026, with a ceiling value of $72.167 million for functional precision medicine and response assays, with ultimate completion on September 28, 2031.
The order is issued under a cost-plus-fixed-fee pricing structure with no set-aside. Place of performance is Frederick, MD. Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research on behalf of NCI and delivers biomedical research execution, facilities infrastructure management, clinical trial support, and specialized manufacturing across the NCI campus and subordinate collaborative sites. The vendor maintains a workforce of approximately 1,830 FTEs and engages subcontractors for specialized activities including molecular diagnostics, laboratory automation and equipment, bioprocess systems, and academic research partnerships with institutions such as the University of Pittsburgh and Children's Hospital of Philadelphia.
Quick answers
Who was awarded contract 75N91026F00034?
75N91026F00034 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 29, 2026.
How much is contract 75N91026F00034 worth?
The government has obligated $72,167,416 on 75N91026F00034.
Is contract 75N91026F00034 an order under another contract?
Yes. 75N91026F00034 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91026F00034 competed?
The extent of competition for 75N91026F00034 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award